ANI Pharmaceuticals, Inc. ANIP
68.67 USD -0.46 (-0.67%)
As ofNov 20, 2026, 11:27 AM EST
68.49 Day range 69.50
67.14 52-week range 87.76
- YTD
- -13.02%
- 1 year
- -12.55%
News
globenewswire.com ANI Pharmaceuticals to Present at Upcoming December Investor Conference PRINCETON, N.J., Nov. 19, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with…
zacks.com Here's Why ANI Pharmaceuticals (ANIP) is a Strong Value Stock The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
defenseworld.net ANI Pharmaceuticals, Inc. $ANIP Stock Acquired by Aberdeen Group plc Aberdeen Group plc boosted its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) by 23.0% in the undefined quarter, according to its most recent disclosure with the Securities and…benzinga.com Guggenheim Maintains Buy on ANI Pharmaceuticals, Raises Price Target to $121 Guggenheim analyst Vamil Divan maintains ANI Pharmaceuticals (NASDAQ:ANIP) with a Buy and raises the price target from $119 to $121.
benzinga.com ANI Pharmaceuticals Q3 2026 Earnings Call Transcript ANI Pharmaceuticals (NASDAQ:ANIP) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…benzinga.com ANI Pharmaceuticals Q3 Adj. EPS $2.70 Beats $2.18 Estimate, Sales $290.800M Beat $280.196M Estimate ANI Pharmaceuticals (NASDAQ:ANIP) reported quarterly earnings of $2.70 per share which beat the analyst consensus estimate of $2.18 by 23.85 percent. This is a 32.35 percent increase over earnings of…
benzinga.com ANI Pharmaceuticals Raises FY2026 Adj EPS Guidance from $9.19-$9.69 to $9.37-$9.71 vs $9.26 Est; Narrows FY2026 Sales Guidance from $1.080B-$1.140B to $1.085B-$1.125B vs $1.102B Est ANI Pharmaceuticals (NASDAQ:ANIP) raises FY2026 Adj EPS guidance from $9.19-$9.69 to $9.37-$9.71 vs $9.26 analyst estimate. Narrows FY2026 sales outlook from $1.080 billion-$1.140 billion to $1.085…
benzinga.com ANI Pharmaceuticals Announces Offer At SEK 11.25 Per Share, About SEK 5.6B ($560M), To Acquire Egetis Therapeutics, Expanding Rare Disease Business Egetis Therapeutics’ lead asset, EMCITATE®, is the first and only approved treatment in U.S. and Europe for peripheral thyrotoxicosis associated with MCT8 deficiency, a rare genetic disorder,…
